# OnCo record msb-gvhd001 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/msb-gvhd001/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "msb-gvhd001", "NCT02336230" ;
  schema:name "MSB-GVHD001"@en ;
  schema:alternateName "MSB-GVHD 001"@en ;
  schema:description "MSB-GVHD001 showed that donor bone marrow stromal cells, given twice a week for a month, helped about seven in ten children whose acute graft-versus-host disease had not settled on steroids, which supported the first US approval of a mesenchymal stromal cell therapy in 2024."@en ;
  schema:url <https://onco.cc/trials/msb-gvhd001/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02336230>, <https://doi.org/10.1016/j.bbmt.2020.01.018>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4e0918f-7444-4694-adeb-d38d98345659> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:technologies <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:drugs <https://onco.cc/drugs/remestemcel-l/> ;
  onco:companies <https://onco.cc/companies/mesoblast/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/allogeneic-transplant/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-msb-gvhd001-bbmt-2020/> .